Deletion of liaR Reverses Daptomycin Resistance in Enterococcus faecium Independent of the Genetic Background

ABSTRACT We have shown previously that changes in LiaFSR, a three-component regulatory system predicted to orchestrate the cell membrane stress response, are important mediators of daptomycin (DAP) resistance in enterococci. Indeed, deletion of the gene encoding the response regulator LiaR in a clinical strain of Enterococcus faecalis reversed DAP resistance (DAP-R) and produced a strain hypersusceptible to antimicrobial peptides. Since LiaFSR is conserved in Enterococcus faecium, we investigated the role of LiaR in a variety of clinical E. faecium strains representing the most common DAP-R genetic backgrounds. Deletion of liaR in DAP-R E. faecium R446F (DAP MIC of 16 μg/ml) and R497F (MIC of 24 μg/ml; harboring changes in LiaRS) strains fully reversed resistance (DAP MICs decreasing to 0.25 and 0.094 μg/ml, respectively). Moreover, DAP at concentrations of 13 μg/ml (achieved with human doses of 12 mg/kg body weight) retained bactericidal activity against the mutants. Furthermore, the liaR deletion derivatives of these two DAP-R strains exhibited increased binding of boron-dipyrromethene difluoride (BODIPY)-daptomycin, suggesting that high-level DAP-R mediated by LiaR in E. faecium involves repulsion of the calcium-DAP complex from the cell surface. In DAP-tolerant strains HOU503F and HOU515F (DAP MICs within the susceptible range but bacteria not killed by DAP concentrations of 5× the MIC), deletion of liaR not only markedly decreased the DAP MICs (0.064 and 0.047 μg/ml, respectively) but also restored the bactericidal activity of DAP at concentrations as low as 4 μg/ml (achieved with human doses of 4 mg/kg). Our results suggest that LiaR plays a relevant role in the enterococcal cell membrane adaptive response to antimicrobial peptides independent of the genetic background and emerges as an attractive target to restore the activity of DAP against multidrug-resistant strains.

[1]  Y. Shamoo,et al.  A variable DNA recognition site organization establishes the LiaR-mediated cell envelope stress response of enterococci to daptomycin , 2015, Nucleic acids research.

[2]  Y. Shamoo,et al.  A liaR deletion restores susceptibility to daptomycin and antimicrobial peptides in multidrug-resistant Enterococcus faecalis. , 2015, The Journal of infectious diseases.

[3]  Ronald N. Jones,et al.  Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. , 2015, Diagnostic microbiology and infectious disease.

[4]  C. Arias,et al.  Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Saghatelian,et al.  Localization of Anionic Phospholipids in Escherichia coli Cells , 2014, Journal of bacteriology.

[6]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[7]  A. Wollam,et al.  Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs , 2014, Antimicrobial Agents and Chemotherapy.

[8]  Ronald N. Jones,et al.  Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). , 2014, International journal of antimicrobial agents.

[9]  Allison D. Griggs,et al.  Emergence of Epidemic Multidrug-Resistant Enterococcus faecium from Animal and Commensal Strains , 2013, mBio.

[10]  Y. Shamoo,et al.  Adaptation of Enterococcus faecalis to Daptomycin Reveals an Ordered Progression to Resistance , 2013, Antimicrobial Agents and Chemotherapy.

[11]  V. Nizet,et al.  β-Lactam Antibiotics Targeting PBP1 Selectively Enhance Daptomycin Activity against Methicillin-Resistant Staphylococcus aureus , 2013, Antimicrobial Agents and Chemotherapy.

[12]  G. Weinstock,et al.  Daptomycin-Resistant Enterococcus faecalis Diverts the Antibiotic Molecule from the Division Septum and Remodels Cell Membrane Phospholipids , 2013, mBio.

[13]  C. Arias,et al.  A liaF Codon Deletion Abolishes Daptomycin Bactericidal Activity against Vancomycin-Resistant Enterococcus faecalis , 2013, Antimicrobial Agents and Chemotherapy.

[14]  G. Weinstock,et al.  Whole-Genome Analysis of a Daptomycin-Susceptible Enterococcus faecium Strain and Its Daptomycin-Resistant Variant Arising during Therapy , 2012, Antimicrobial Agents and Chemotherapy.

[15]  R. Daum,et al.  VraT/YvqF Is Required for Methicillin Resistance and Activation of the VraSR Regulon in Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[16]  C. Arias,et al.  Correlation between Mutations in liaFSR of Enterococcus faecium and MIC of Daptomycin: Revisiting Daptomycin Breakpoints , 2012, Antimicrobial Agents and Chemotherapy.

[17]  J. Pogliano,et al.  Daptomycin-Mediated Reorganization of Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins , 2012, Journal of bacteriology.

[18]  X. Qin,et al.  Genomic and SNP Analyses Demonstrate a Distant Separation of the Hospital and Community-Associated Clades of Enterococcus faecium , 2012, PloS one.

[19]  G. Bierbaum,et al.  Purification and Activity Testing of the Full-Length YycFGHI Proteins of Staphylococcus aureus , 2012, PloS one.

[20]  R. Rosato,et al.  VraSR Two-Component Regulatory System Contributes to mprF-Mediated Decreased Susceptibility to Daptomycin in In Vivo-Selected Clinical Strains of Methicillin-Resistant Staphylococcus aureus , 2011, Antimicrobial Agents and Chemotherapy.

[21]  G. Weinstock,et al.  Genetic basis for in vivo daptomycin resistance in enterococci. , 2011, The New England journal of medicine.

[22]  Anna-Barbara Hachmann,et al.  Reduction in Membrane Phosphatidylglycerol Content Leads to Daptomycin Resistance in Bacillus subtilis , 2011, Antimicrobial Agents and Chemotherapy.

[23]  P. Varaldo,et al.  Striking “Seesaw Effect” between Daptomycin Nonsusceptibility and β-Lactam Susceptibility in Staphylococcus haemolyticus , 2011, Antimicrobial Agents and Chemotherapy.

[24]  M. Gilmore,et al.  Genetic Basis for Daptomycin Resistance in Enterococci , 2011, Antimicrobial Agents and Chemotherapy.

[25]  L. Rice,et al.  The hylEfm gene in pHylEfm of Enterococcus faecium is not required in pathogenesis of murine peritonitis , 2011, BMC Microbiology.

[26]  Clsi Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[27]  Janine Kirstein,et al.  In-Depth Profiling of the LiaR Response of Bacillus subtilis , 2010, Journal of bacteriology.

[28]  C. Arias,et al.  Management of multidrug-resistant enterococcal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  H. Kalbacher,et al.  The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion , 2009, PLoS pathogens.

[30]  Anna-Barbara Hachmann,et al.  Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin , 2009, Antimicrobial Agents and Chemotherapy.

[31]  L. Rice Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.

[32]  G. Dunny,et al.  Development of a host-genotype-independent counterselectable marker and a high-frequency conjugative delivery system and their use in genetic analysis of Enterococcus faecalis. , 2007, Plasmid.

[33]  G. Wortmann,et al.  De Novo Daptomycin Nonsusceptibility in a Clinical Isolate , 2006, Journal of Clinical Microbiology.

[34]  J. Quinn,et al.  Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Jorgensen,et al.  Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy , 2005, Antimicrobial Agents and Chemotherapy.

[36]  Kouji Matsumoto,et al.  Cardiolipin Domains in Bacillus subtilis Marburg Membranes , 2004, Journal of bacteriology.

[37]  R. Birke,et al.  Cardiolipin binds nonyl acridine orange by aggregating the dye at exposed hydrophobic domains on bilayer surfaces , 2001, FEBS letters.

[38]  William Dowhan,et al.  Visualization of Phospholipid Domains inEscherichia coli by Using the Cardiolipin-Specific Fluorescent Dye 10-N-Nonyl Acridine Orange , 2000, Journal of bacteriology.